Analysts predict Exagen's revenue growth to decelerate significantly, with an expected annual growth of 3.1% till 2024, compared to its past five-year growth rate of 7.5%. This is slower than the projected 18% annual growth of its industry peers.
The low P/S ratio and slower revenue growth have led to pessimism among shareholders about the company's future prospects. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
Exagen's low P/S ratio indicates investor concerns over below-average expected revenue growth. For a higher P/S ratio or share price, conditions would need to improve. The recent drop in share price may be due to this potentially less favorable outlook.
QUICK SCALP 4 $XGN — STOCK & OPTION PLAY ALERT ON: $4.06 ON THE WATCH: $4.14 🥇 SIGNED OF MORE UPTREND: $4.24 NEED IT TO BREAK OVER: $4.38 key indicator for MORE uptrend $4.64 confirmation uptrend - $4.84 mini breakout - $4.97.$Exagen(XGN.US)$
Exagen股票討論區
$Exagen(XGN.US)$770k remaining float and only 300 watchers on board. People just finding this one
$Cosmos Health(COSM.US)$Lets see what she got, still hold in
ALERT ON: $4.06
ON THE WATCH: $4.14
🥇 SIGNED OF MORE UPTREND: $4.24
NEED IT TO BREAK OVER: $4.38
key indicator for MORE uptrend $4.64
confirmation uptrend - $4.84
mini breakout - $4.97. $Exagen(XGN.US)$
暫無評論